Expression of EPK in Recurrent Miscarriage

Overview

The present study is based on hypotheses that some as yet unknown genetic factors may result in recurrent miscarriage (RM). Consequently, the main aim of this study was to gain new information about the underlying genetic causes of RM in the Egyptian population and to investigate the expression of ERK and p-ERK protein in human placenta and their corresponding tissue, to assess the significance of MAPK signal pathway in progression of recurrent miscarriage and PI3K-Akt Pathway.

Full Title of Study: “MAP Kinase Signaling Pathways Through ERK and p-ERK Protein in Human Placenta of Women With Recurrent Miscarriage”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2015

Interventions

  • Other: Investigate the MAP kinase signaling pathways through ERK and p-ERK proteins

Arms, Groups and Cohorts

  • Recurrent miscarriage group
    • Women with previous history of RM, defined as two or more consecutive miscarriages
  • Control group
    • Women with no history of RM

Clinical Trial Outcome Measures

Primary Measures

  • The levels of ERK and AKT in placenta
    • Time Frame: 48 hours

Participating in This Clinical Trial

Inclusion Criteria

1. Gestational age less than 12 weeks. 2. no uterine abnormalities (examined by ultrasonography or hysterosonogram) 3. previous history of RM, defined as two or more consecutive miscarriages Exclusion Criteria:

1. Gestational age 12 weeks or more. 2. Endocrine etiology like (thyroid dysfunction, and uncontrolled diabetes mellitus). 3. Antiphospholipid syndrome, inherited thrombophilias, alloimmune causes. 4. Uterine anatomic anomalies

Gender Eligibility: Female

Minimum Age: 20 Years

Maximum Age: 40 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Assiut University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Ahmed Mohamed Abbas, Dr – Assiut University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.